The altered homeostatic theory: A hypothesis proposed to be useful in understanding and preventing ischemic heart disease, hypertension, and diabetes - including reducing the risk of age and atherosclerosis

Medical Hypotheses

Volumn 68, Issue 2, 2007, Pages 415-433

  Hellstrom, H R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BILE ACID SEQUESTRANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROGESTERONE;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BONE DENSITY; CANCER; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; COGNITION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; DRUG SCREENING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LOW DRUG DOSE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SYMPATHETIC TONE; THROMBOSIS; VALIDITY; VASOCONSTRICTION;

AGING; ATHEROSCLEROSIS; DIABETES MELLITUS; HOMEOSTASIS; HUMANS; HYPERTENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MYOCARDIAL ISCHEMIA; PITUITARY-ADRENAL SYSTEM; RISK FACTORS;

EID: 33845303115     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.05.031     Document Type: Article

References (264)

1. Hellstrom H.R. The altered homeostatic theory: a holistic approach to multiple diseases, including atherosclerosis, ischemic diseases, and hypertension. Med Hypotheses 53 (1999) 194-199
2. Hellstrom H.R. Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. Med Hypotheses 60 (2003) 12-25
3. Lefkowitz R.J., Hoffman B.B., and Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Gilman A.G. (Eds). The pharmacological basis of therapeutics (1996), McGraw-Hill, New York 105-139
4. Selye H. The stress of life: revised edition (1978), McGraw-Hill Book Co, New York p. 1
5. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med 338 (1998) 171-179
6. Remme W.J. The sympathetic nervous system and ischaemic heart disease. Eur Heart J 19 Suppl. F (1998) F62-F71
7. Julius S. The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension. Clin Exp Hypertens 17 (1995) 375-386
8. Esler M., Rumantir M., Wiesner G., Kaye D., Hastings J., and Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14 (2001) 304S-309S
9. Expert panel on detection evaluation and treatment of high blood cholesterol. Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): third report of the National Cholesterol Education Program (NCEP) Expert Panel. Circulation 106 (2002) 3145-3421
10. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID Trial. JAMA 295 (2006) 1556-1565
11. Cannon W.B. Bodily changes in pain, hunger, fear and rage. An account of recent researches into the function of emotional excitement. 2nd ed. (1953), Charles T. Branford Co, Boston p. 1
12. Hoffman B.B., and Lefkowitz R.J. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Gilman A.G. (Eds). The pharmacological basis of therapeutics (1996), McGraw-Hill, New York 199-248
13. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16 (2002) 622-653
14. Verma S., and Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 (2002) 546-549
15. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
16. Gutstein D.E., and Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 41 (1999) 323-333
17. Hellstrom H.R. Can the premises of the spasm of resistance vessel concept permit improvement in the treatment and prevention of ischemic heart disease?. Med Hypotheses 60 (2003) 36-51
18. 2. Science 296 (2002) 539-541
19. Brown N.J., and Vaughan D.E. Prothrombotic effects of angiotensin. Adv Intern Med 45 (2000) 419-429
20. Campbell D.J., Krum H., and Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 (2005) 315-320
21. Freedman J.E. Molecular regulation of platelet-dependent thrombosis. Circulation 112 (2005) 2725-2734
22. Mcfarlane R.G. Haemostasis. In: Biggs R. (Ed). Human blood coagulation haemostasis and thrombosis (1976), Blackwell Scientific Publications, Oxford 608-654
23. Kim J., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation 113 (2006) 1888-1904
24. Hellstrom H.R. Cholesterol, an important but relatively overemphasized risk factor for ischemic heart disease. Med Hypotheses 57 (2001) 593-601
25. Piepot H.A., Groeneveld A.B., van Lambalgen A.A., and Sipkema P. Tumor necrosis factor-alpha impairs endothelium-dependent relaxation of rat renal arteries, independent of tyrosine kinase. Shock 17 (2002) 394-398
26. Zhang Z.H., Wei S.G., Francis J., and Felder R.B. Cardiovascular and renal sympathetic activation by blood-borne TNF-α in rat: the role of central prostaglandins. Am J Physiol 284 (2003) R916-R927
27. Ridker P.M. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence?. Circulation 97 (1998) 1671-1674
28. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
29. ι2, a possible marker for parasympathetic responsiveness. Circulation 108 (2003) 2743-2746
30. Kishi T., Hirooka Y., Mukai Y., Shimokawa H., and Takeshita A. Atorvastatin causes depressor and sympathoinhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 21 (2003) 379-386
31. Little P.J., Topliss D.J., Mudaliar S., and Law R.E. Peroxisome proliferator-activated receptors and diabetic vasculature. In: Marso S.P., and Stern D.M. (Eds). Diabetes and cardiovascular disease integrating science and clinical medicine (2004), Lippincott Williams & Wilkins, Philadelphia 75-91
32. Nagai Y., Sugiyama Y., Nakatsumit Y., Abe T., and Nomura G. Rapid amelioration of muscle sympathetic nerve activity by pioglitazone in an obese Type 2 diabetic patient. Diabet Med 20 (2003) 868-869
33. Bruckert E., Giral P., and Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 107 (2003) 3124-3128
34. Zhang X., Xie Y.W., Nasjletti A., Xu X., Wolin M.S., and Hintze T.H. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 95 (1997) 176-182
35. Rosmond R. Stress induced disturbances of the HPA axis: a pathway to Type 2 diabetes?. Med Sci Monit 9 (2003) RA35-RA39
36. Smith G.D., Ben-Shlomo Y., Beswick A., Yarnell J., Lightman S., and Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly Study. Circulation 112 (2005) 332-340
37. Kougias P., Chai H., Lin P.H., Yao Q., Lumsden A.B., and Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 126 (2005) 121-129
38. Kreier F., Fliers E., Voshol P.J., et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J Clin Invest 110 (2002) 1243-1250
39. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
40. Knudson J.D., Dincer U.D., Zhang C., et al. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol 289 (2005) H48-H56
41. Ambrose J.A. A new paradigm for plaque stabilization. Circulation 105 (2002) 2000-2004
42. Hellstrom H.R. The spasm of resistance vessel concept of ischemic heart disease and other ischemic diseases. Med Hypotheses 33 (1990) 31-41
43. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340 (1999) 115-126
44. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
45. Black P.H., and Garbutt L.D. Stress, inflammation and cardiovascular disease. J Psychosom Res 52 (2002) 1-23
46. Rajkumar C., Simpson H., Jennings G.L., and Dart A.M. Postprandial silent ischaemia following a fatty meal in patients with recently diagnosed coronary artery disease. J Hum Hypertens 14 (2000) 391-394
47. Deanfield J.E., Shea M., Kensett M., et al. Silent myocardial ischaemia due to mental stress. Lancet 2 (1984) 1001-1005
48. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1425
49. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
50. Morrow L.A., and Halter J.B. Diabetes in the older adult. Geriatrics 43 Suppl. (1988) 57-65
51. Esler M., Hastings J., Lambert G., Kaye D., Jennings G., and Seals D.R. The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover. Am J Physiol 282 (2002) R909-R916
52. Golomb E., Kruglikova A., Dvir D., Parnes N., and Abramovici A. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 34 (1998) 214-221
53. Michel M.C., Heemann U., Schumacher H., Mehlburger L., and Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 172 (2004) 1390-1393
54. Goldsmith R.L., Bloomfield D.M., and Rosenwinkel E.T. Exercise and autonomic function. Coron Artery Dis 11 (2000) 129-135
55. Platz E.A., Kawachi I., Rimm E.B., et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 158 (1998) 2349-2356
56. Dinenno F.A., Dietz N.M., and Joyner M.J. Aging and forearm postjunctional α-adrenergic vasoconstriction in healthy men. Circulation 106 (2002) 1349-1354
57. Abate N.I., Mansour Y.H., Tuncel M., et al. Overweight and sympathetic overactivity in black Americans. Hypertension 38 (2001) 379-383
58. Dishman R.K., Nakamura Y., Jackson E.M., and Ray C.A. Blood pressure and muscle sympathetic nerve activity during cold pressor stress: fitness and gender. Psychophysiology 40 (2003) 370-380
59. Oda Y., Asanoi H., Ueno H., et al. Pulse-synchronous sympathetic burst power as a new index of sympathoexcitation in patients with heart failure. Am J Physiol 287 (2004) H1821-H1827
60. Franceschi C., Bonafè M., Valensin S., et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908 (2000) 244-254
61. Cornelis M.C., El-Sohemy A., Kabagambe E.K., and Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295 (2006) 1135-1141
62. Law M.R., and Wald N.J. Risk factor thresholds: their existence under scrutiny. BMJ 324 (2002) 1570-1576
63. Franco O.H., Bonneux L., de Laet C., Peeters A., Steyerberg E.W., and Mackenbach J.P. The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 329 (2004) 1447-1450
64. Robinson J.G., and Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 95 (2005) 373-378
65. Julius S., Nesbitt S.D., Egan B.M., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
66. Vijan S., and Hayward R.A. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Int Med 140 (2004) 650-658
67. Khan A., Safdar M., Ali Khan M.M., Khattak K.N., and Anderson R.A. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 26 (2003) 3215-3218
68. van de Borne P., Mark A.L., Montano N., Mion D., and Somers V.K. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension 29 (1997) 1278-1283
69. Shepherd C.E., Piguet O., Broe G.A., et al. Histocompatibility antigens, aspirin use and cognitive performance in non-demented elderly subjects. J Neuroimmunol 148 (2004) 178-182
70. Carbone L.D., Tylavsky F.A., Cauley J.A., et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18 (2003) 1795-1802
71. Nilsson S.E., Johansson B., Takkinen S., et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol 59 (2003) 313-319
72. Psychari S.N., Apostolou T.S., Sinos L., Hamodraka E., Liakos G., and Kremastinos D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95 (2005) 764-767
73. Gonzalez-Pérez A., Garcia Rodríguez L.A., and Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3 (2003) 28
74. Ridker P.M. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 105 (2002) 2-4
75. Neel J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress?. Am J Hum Genet 14 (1962) 353-362
76. Fernández-Real J.M., and Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42 (1999) 1367-1374
77. Cordain L., Gotshall R.W., Eaton S.B., and Eaton III S.B. Physical activity, energy expenditure and fitness: an evolutionary perspective. Int J Sports Med 19 (1998) 328-335
78. Eaton S.B., Eaton III S.B., Sinclair A.J., Cordain L., and Mann N.J. Dietary intake of long-chain polyunsaturated fatty acids during the paleolithic. World Rev Nutr Diet 83 (1998) 12-23
79. Eaton S.B., and Cordain L. Evolutionary aspects of diet: old genes, new fuels: nutritional changes since agriculture. World Rev Nutr Diet 81 (1997) 26-37
80. Lenfant C. A new challenge for America: the National Cholesterol Education Program. Circulation 73 (1986) 855-856
81. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 148 (1988) 36-69
82. Report of the expert panel on population strategies for blood cholesterol reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 83 (1991) 2154-2232
83. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults national cholesterol education program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 89 (1994) 1333-1445
84. Hopkins P.N., and Williams R.R. A survey of 246 suggested coronary risk factors. Atherosclerosis 40 (1981) 1-52
85. de Lorgeril M., Salen P., Martin J.L., Monjaud I., Delaye J., and Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99 (1999) 779-785
86. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
87. Leibowitz J.O. The history of coronary heart disease (1970), University of California Press, Berkeley p. 1
88. Heberden W. Commentaries on the history and cure of diseases, 1802. In: Willius F.A., and Keys T.E. (Eds). Classics of cardiology (1941), Dover Publications, New York 221-224
89. Berenson A. Merck is winner in Vioxx lawsuit on heart attack. The New York Times; November 4, 2005.
90. Chrousos G.P., and Gold P.W. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 267 (1992) 1244-1252
91. Hijmering M.L., Stroes E.S., Olijhoek J., Hutten B.A., Blankestijn P.J., and Rabelink T.J. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39 (2002) 683-688
92. Julius S., and Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med 32 (2000) 365-370
93. Iaccarino G., Ciccarelli M., Sorriento D., et al. AKT participates in endothelial dysfunction in hypertension. Circulation 109 (2004) 2587-2593
94. De Curtis A., D'Adamo M.C., Amore C., et al. Experimental arterial thrombosis in genetically or diet induced hyperlipidemia in rats - role of vitamin K-dependent clotting factors and prevention by low-intensity oral anticoagulation. Thromb Haemost 86 (2001) 1440-1448
95. Hutter R., Valdiviezo C., Sauter B.V., et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 109 (2004) 2001-2008
96. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 374-381
97. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
98. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridler P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
99. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
100. Esmon C.T. Crosstalk between inflammation and thrombosis. Maturitas 47 (2004) 305-314
101. Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 290 (2003) 3000-3002
102. Julius S., and Gudbrandsson T. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk. J Cardiovasc Pharmacol 20 Suppl. 8 (1992) S40-S48
103. Boden G., and Hoeldtke R.D. Nerves, fat, and insulin resistance. N Engl J Med 349 (2003) 1966-1967
104. Sobel B.E. Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol 84 (1999) 37J-41J
105. May O., Arildsen H., and Møller M. Parasympathetic function during deep breathing in the general population: relation to coronary risk factors and normal range. J Intern Med 245 (1999) 287-294
106. Wilkerson W.R., and Sane D.C. Aging and thrombosis. Semin Thromb Hemost 28 (2002) 555-567
107. Gostynski M., Gutzwiller F., Kuulasmaa K., et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes 28 (2004) 1082-1090
108. Røder M.E., Schwartz R.S., Prigeon R.L., and Kahn S.E. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab 85 (2000) 2275-2280
109. Paradis G., Lambert M., O'Loughlin J., et al. Blood pressure and adiposity in children and adolescents. Circulation 110 (2004) 1832-1838
110. Eckel R.H., Barouch W.W., and Ershow A.G. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 105 (2002) 2923-2928
111. Alvarez G.E., Beske S.D., Ballard T.P., and Davy K.P. Sympathetic neural activation in visceral obesity. Circulation 106 (2002) 2533-2536
112. Pathak A., Smih F., Galinier M., et al. Insulin downregulates M(2)-muscarinic receptors in adult rat atrial cardiomyocytes: a link between obesity and cardiovascular complications. Int J Obes Relat Metab Discord 29 (2005) 176-182
113. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
114. Barengo N.C., Hu G., Kastarinen M., et al. Low physical activity as a predictor for antihypertensive drug treatment in 25-64-year-old populations in eastern and south-western Finland. J Hypertens 23 (2005) 293-299
115. Sullivan P.W., Morrato E.H., Ghushchyan V., Wyatt H.R., and Hill J.O. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 28 (2005) 1599-1603
116. Hellstrom H.R. Evidence in support of the spasm of resistance vessel concept of ischemic heart disease: an update in 1993. Med Hypotheses 41 (1993) 11-22
117. Goldsmith R.L., Bigger Jr. J.T., Steinman R.C., and Fleiss J.L. Comparison of 24-hour parasympathetic activity in endurance-trained and untrained young men. J Am Coll Cardiol 20 (1992) 552-558
118. Lee K.W., and Lip G.Y. Effects of lifestyle on hemostasis, fibinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163 (2003) 2368-2392
119. Das U.N. Anti-inflammatory nature of exercise. Nutrition 20 (2004) 323-326
120. LaMonte M.J., Blair S.N., and Church T.S. Physical activity and diabetes prevention. J Appl Physiol 99 (2005) 1205-1213
121. Rozanski A., Blumenthal J.A., and Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99 (1999) 2192-2217
122. Yan L.L., Liu K., Matthews K.A., Daviglus M.L., Ferguson T.F., and Kiefe C.I. Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA 290 (2003) 2138-2148
123. Mezzacappa E.S., Kelsey R.M., Katkin E.S., and Sloan R.P. Vagal rebound and recovery from psychological stress. Psychosom Med 63 (2001) 650-657
124. Black P.H. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 17 (2003) 350-364
125. Haire-Joshu D., Glascow R.E., and Tibbs T.L. Smoking and diabetes. Diabetes Care 22 (1999) 1887-1898
126. Hjemdahl P. Smoking, nicotine and thrombotic risk - a role for platelet dependent thrombin generation?. Eur Heart J 22 (2001) 16-18
127. Tsiara S., Elisaf M., and Mikhailidis D.P. Influence of smoking on predictors of vascular disease. Angiology 54 (2003) 507-530
128. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 45 (2003) 405-413
129. Manfredini R., Gallerani M., Portaluppi F., and Fersini C. Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Ann N Y Acad Sci 783 (1996) 141-158
130. la Fleur S.E., Kalsbeek A., Wortel J., Fekkes M.L., and Buijs R.M. A daily rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. Diabetes 50 (2001) 1237-1243
131. Trotti R., Rondanelli M., Cuzzoni G., Ferrari E., and d'Eril G.M. Circadian temporal organization of lipidic fractions in elderly people: entrainment to the dietary schedule. Aging Clin Exp Res 14 (2002) 94-99
132. Panzer S.E., Dodge A.M., Kelly E.A., and Jarjour N.N. Circadian variation of sputum inflammatory cells in mild asthma. J Allergy Clin Immunol 111 (2003) 308-312
133. Spencer F.A., Goldberg R.J., Becker R.C., and Gore J.M. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol 31 (1998) 1226-1233
134. 1A receptor deficiency attenuates cold-induced hypertension. Am Journal Physiol 288 (2005) R433-R439
135. 1c values. Am J Epidemiol 161 (2005) 565-574
136. Kawahara J., Sano H., Fukuzaki H., Saito K., and Hirouchi H. Acute effects of exposure to cold on blood pressure, platelet function and sympathetic nervous activity in humans. Am J Hypertens 2 (1989) 724-726
137. Zhu Z., Zhu S., Zhu J., van der Giet M., and Tepel M. Endothelial dysfunction in cold-induced hypertensive rats. Am J Hypertens 15 (2002) 176-180
138. Gyllerup S., Lanke J., Lindholm L.H., and Schersten B. Cold climate is an important factor in explaining regional differences in coronary mortality even if serum cholesterol and other established risk factors are taken into account. Scot Med J 38 (1993) 169-172
139. Mercer J.B., Østerud B., and Tveita T. The effect of short-term cold exposure on risk factors for cardiovascular disease. Thromb Res 95 (1999) 93-104
140. Torsoni M.A., Carvalheira J.B., Pereira-Da-Silva M., de Carvalho-Filho M.A., Saad M.J., and Velloso L.A. Molecular and functional resistance to insulin in hypothalamus of rats exposed to cold. Am J Physiol 285 (2003) E216-E223
141. Hayden M., Pignone M., Phillips C., and Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136 (2002) 161-172
142. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
143. Chiquette E., Ramirez G., and DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164 (2004) 2097-2104
144. Michels K.B., and Manson J.E. Postmenopausal hormone therapy: a reversal of fortune. Circulation 107 (2003) 1830-1833
145. Thompson P.D., Buchner D., Piña I.L., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107 (2003) 3109-3116
146. de Lorgeril M., and Salen P. Is alcohol anti-inflammatory in the context of coronary heart disease?. Heart 90 (2004) 355-357
147. He K., Song Y., Daviglus M.L., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109 (2004) 2705-2711
148. Ros E., Núñez I., Pérez-Heras A., et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation 109 (2004) 1609-1614
149. Sies H., Schewe T., Heiss C., and Kelm M. Cocoa polyphenols and inflammatory mediators. Am J Clin Nutr 81 Suppl. (2005) 304S-312S
150. Bybee K.A., Kopecky S.L., Williams B.A., Murphy J.G., and Wright R.S. Reduced creatine kinase release with statin use at the time of myocardial infarction. Int J Cardiol 96 (2004) 461-466
151. Brouwer M.A., van den Bergh P.J., Aengevaeren W.R., et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 106 (2002) 659-665
152. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 36 (2000) 1529-1535
153. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
154. Golomb B.A., Ritchie J.B., Criqui M.H., and Dimsdale J.E. Statins lower blood pressure: results from the UCSD statin study. Circulation 110 Suppl. III (2004) III-402 Abstract
155. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
156. Wyss J.M., and Carlson S.H. Effects of hormone replacement therapy on the sympathetic nervous system and blood pressure. Curr Hypertens Rep 5 (2003) 241-246
157. Franco V., Oparil S., and Carretero O.A. Hypertensive therapy: part II. Circulation 109 (2004) 3081-3088
158. Matthews K.A., Katholi C.R., McCreath H., et al. Blood pressure reactivity to psychological stress predicts hypertension in the CARDIA study. Circulation 110 (2004) 74-78
159. Psaltopoulou T., Naska A., Orfanos P., Trichopoulos D., Mountokalakis T., and Trichopoulou A. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 80 (2004) 1012-1018
160. Al-Awwadi N.A., Bornet A., Azay J., et al. Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat. J Agric Food Chem 52 (2004) 5593-5597
161. Magen E., Viskoper R., Mishal J., et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 6 (2004) 742-746
162. Hermida R.C., Ayala D.E., Calvo C., et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension 41 (2003) 1259-1267
163. Krantz D.S., and McCeney M.K. Effects of psychological and social factors on organic disease: a critical assessment of research on coronary heart disease. Annu Rev Psychol 53 (2002) 341-369
164. Geleijnse J.M., Giltay E.J., Grobbee D.E., Donders A.R., and Kok F.J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20 (2002) 1493-1499
165. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
166. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64 (2004) 2537-2565
167. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51 (2002) 2796-2803
168. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Int Med 138 (2003) 1-9
169. Sjöström L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 351 (2004) 2683-2693
170. Wales J.K. Does psychological stress cause diabetes?. Diabet Med 12 (1995) 109-112
171. Howard A.A., Arnsten J.H., and Gourevitch M.N. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 140 (2004) 211-219
172. Jiang R., Manson J.E., Stampfer M.J., Liu S., Willett W.C., and Hu F.B. Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA 288 (2002) 2554-2560
173. Biesalski H.K. Diabetes preventive components in the Mediterranean diet. Eur J Nutr 43 Suppl. 1 (2004) I26-I30
174. Paniagua J.A., López-Miranda J., Escribano A., et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 51 (2002) 2596-2603
175. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
176. Yki-Järvinen H. Thiazolidinediones. N Eng J Med 351 (2004) 1106-1118
177. Inui A., Kitaoka H., Majima M., et al. Effect of the Kobe earthquake on stress and glycemic control in patients with diabetes mellitus. Arch Intern Med 158 (1998) 274-278
178. Abelson K.S., Kommalage M., and Höglund U. Spinal cholinergic involvement after treatment with aspirin and paracetamol in rats. Neurosci Lett 368 (2004) 116-120
179. Kontopoulos A.G., Athyros V.G., Papageorgiou A.A., and Boudoulas H. Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction. Am J Cardiol 84 (1999) 1164-1169
180. Manhem K., Brandin L., Ghanoum B., Rosengren A., and Gustafsson H. Acute effects of transdermal estrogen on hemodynamic and vascular reactivity in elderly postmenopausal healthy women. J Hypertens 21 (2003) 387-394
181. Laaksonen D.E., Laitinen T., Schönberg J., Rissanen A., and Niskanen L.K. Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome. J Hypertens 21 (2003) 371-378
182. Sakakibara M., Takeuchi S., and Hayano J. Effect of relaxation training on cardiac parasympathetic tone. Psychophysiology 31 (1994) 223-228
183. Murata K., Araki S., Yokoyama K., Sata F., Yamashita K., and Ono Y. Autonomic neurotoxicity of alcohol assessed by heart rate variability. J Auton Nerv Syst 48 (1994) 105-111
184. Das U.N. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how?. Prostaglandins Leukot Essent Fatty Acids 63 (2000) 351-362
185. Vongpatanasin W., Tuncel M., Mansour Y., Arbique D., and Victor R.G. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 103 (2001) 2903-2908
186. Trombetta I.C., Batalha L.T., Rondon M.U., et al. Weight loss improves neurovascular and muscle metaboreflex control in obesity. Am J Physiol 285 (2003) H974-H982
187. Lucini D., Covacci G., Milani R., Mela G.S., Malliani A., and Pagani M. A controlled study of the effects of mental relaxation on autonomic excitatory responses in healthy subjects. Psychosom Med 59 (1997) 541-552
188. Jennings G.L., Chin-Dusting J.P., Kingwell B.A., et al. Modulation of vascular function by diet and exercise. Clin Exp Hypertens 19 (1997) 727-737
189. Quyyumi A.A. Effects of aspirin on endothelial dysfunction in atherosclerosis. Am J Cardiol 82 (1998) 31S-33S
190. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
191. Higashi Y., Sasaki S., Kurisu S., et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation 100 (1999) 1194-1202
192. Ziccardi P., Nappo F., Giugliano G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
193. Spieker L.E., Hürlimann D., Ruschitzka F., et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 105 (2002) 2817-2820
194. Teragawa H., Fukuda Y., Matsuda K., et al. Effect of alcohol consumption on endothelial function in men with coronary artery disease. Atherosclerosis 165 (2002) 145-152
195. Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292 (2004) 1440-1446
196. 4 and inhibits thromboxane in a randomized human trial. PNAS 101 (2004) 15178-15183
197. Gryglewski R.J., Świe{ogonek}s J., Uracz W., Chłopicki S., and Marcinkiewicz E. Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats. Thromb Res 110 (2003) 323-329
198. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 201-210
199. Lacoste L., Hung J., and Lam J.Y. Acute and delayed antithrombotic effects of alcohol in humans. Am J Cardiol 87 (2001) 82-85
200. Mruk J.S., Webster M.W., Heras M., Reid J.M., Grill D.E., and Chesebro J.H. Flavone-8-acetic acid (flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo. Circulation 101 (2000) 324-328
201. Hundal R.S., Petersen K.F., Mayerson A.B., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109 (2002) 1321-1326
202. Kon V., and Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 13 (2004) 291-297
203. Khan M., Xu Y., Edwards G., Urquhart R., and Mariz S. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. Int J Clin Pract 58 (2004) 907-912
204. Faludi A.A., Aldrighi J.M., Bertolami M.C., et al. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis 177 (2004) 89-96
205. Klein S., Burke L.E., Bray G.A., et al. Clinical implications of obesity with specific focus on cadiovascular disease. A statement for professional from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation 110 (2004) 2952-2967
206. Wannamethee S.G., Lowe G.D., Shaper G., et al. The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in older men. Thromb Haemost 90 (2003) 1080-1087
207. Tapsell L.C., Gillen L.J., Patch C.S., et al. Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care 27 (2004) 2777-2783
208. Chiba H., Uehara M., Wu J., et al. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr 133 (2003) 1892-1897
209. Lefer D.J. Statins as potent antiinflammatory drugs. Circulation 106 (2002) 2041-2042
210. Hsueh W.A., Lyon C.J., and Quiñones M.J. Insulin resistance and the endothelium. Am J Med 117 (2004) 109-117
211. Thomas T.N., Rhodin J.A., Clark L., Garces A., and Bryant M. A comparison of the anti-inflammatory activities of conjugated estrogens and 17-β estradiol. Inflamm Res 52 (2003) 452-460
212. Kasapis C., and Thompson P.D. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 45 (2005) 1563-1569
213. Lutgendorf S., Logan H., Kirchner H.L., et al. Effects of relaxation and stress on the capsaicin-induced local inflammatory response. Psychosom Med 62 (2000) 524-534
214. Albert M.A., Glynn R.J., and Ridker P.M. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107 (2003) 443-447
215. Greenfield J.R., Samaras K., Jenkins A.B., Kelly P.J., Spector T.D., and Campbell L.V. Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator?. Diabetes Care 26 (2003) 2734-2740
216. Raikkonen K., Keltikangas-Jarvinen L., Adlercreutz H., and Hautanen A. Psychosocial stress and the insulin resistance syndrome. Metabolism 45 (1996) 1533-1538
217. Sirtori C.R., and Galli C. N-3 fatty acids and diabetes. Biomed Pharmacother 56 (2002) 397-406
218. Garcia-Lorda P., Megias Rangil I., and Salas-Salvado J. Nut consumption, body weight and insulin resistance. Eur J Clin Nutr 57 Suppl. 1 (2003) S8-S11
219. Starr J.M., McGurn B., Whiteman M., Pattie A., Whalley L.J., and Deary I.J. Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry (2004) 327-332
220. Tedesco M.A., Ratti G., Di Salvo G., and Natale F. Does the angiotensin II receptor antagonist losartan improve cognitive function?. Drugs Aging 19 (2002) 723-732
221. Fillit H.M., Butler R.N., O'Connell A.W., et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc 77 (2002) 681-696
222. Weuve J., Kang J.H., Manson J.E., Breteler M.M., Ware J.H., and Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA 292 (2004) 1454-1461
223. Bagger Y.Z., Tanko L.B., Alexandersen P., Qin G., and Christiansen C. The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res 12 (2004) 1519-1526
224. Stampfer M.J., Kang J.H., Chen J., Cherry R., and Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 352 (2005) 245-253
225. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 4 (2000) 202-207
226. Joseph J.A., Shukitt-Hale B., and Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr 81 Suppl. (2005) 313S-316S
227. Lupattelli G., Scarponi A.M., Vaudo G., et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 53 (2004) 744-748
228. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. Q J Med 98 (2005) 467-484
229. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344 (2001) 276-285
230. MacKelvie K.J., Petit M.A., Khan K.M., Beck T.J., and McKay H.A. Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys. Bone 34 (2004) 755-764
231. Guney E., Kisakol G., Ozgen G., Yilmaz C., Yilmaz R., and Kabalak T. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg 13 (2003) 383-388
232. Bakhireva L.N., Barrett-Connor E., Kritz-Silverstein D., and Morton D.J. Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 26 (2004) 436-442
233. Judex S., Wohl G.R., Wolff R.B., Leng W., Gillis A.M., and Zernicke R.F. Dietary fish oil supplementation adversely affects cortical bone morphology and biomechanics in growing rabbits. Calcif Tissue Int 66 (2000) 443-448
234. Rea T.D., Breitner J.C., Psaty B.M., et al. Statin use and the risk of incident dementia. Arch Neurol 62 (2005) 1047-1051
235. Broe G.A., Grayson D.A., Creasey H.M., et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57 (2000) 1586-1591
236. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 20 (2000) 558-567
237. Zandi P.P., Carlson M.C., Plassman B.L., et al. Hormone replacement therapy and incidence of Alzheimer Disease in older women: the Cache County Study. JAMA 288 (2002) 2123-2129
238. Abbott R.D., White L.R., Ross G.W., Masaki K.H., Curb J.D., and Petrovitch H. Walking and dementia in physically capable elderly men. JAMA 292 (2004) 1447-1453
239. Wilson R.S., Evans D.A., Bienias J.L., Mendes de Leon C.F., Schneider J.A., and Bennett D.A. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 61 (2003) 1479-1485
240. Luchsinger J.A., Tang M.X., Siddiqui M., Shea S., and Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc 52 (2004) 540-546
241. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60 (2003) 940-946
242. Panza F., Solfrizzi V., Colacicco A.M., et al. Mediterranean diet and cognitive decline. Public Health Nutr 7 (2004) 959-963
243. Weinreb O., Mandel S., Amit T., and Youdim M.B. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15 (2004) 506-516
244. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
245. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
246. Houghton J.L., Devlin C.W., Besson W.T., et al. Possible triggering of paroxysmal atrial fibrillation in normal hearts by psychological stressors: a report of two cases. Am J Med Sci 300 (1990) 234-236
247. Frost L., and Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164 (2004) 1993-1998
248. Mozaffarian D., Psaty B.M., Rimm E.B., et al. Fish intake and risk of incident atrial fibrillation. Circulation 110 (2004) 368-373
249. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
250. Lindberg H., Nielsen D., Jensen B.V., Eriksen J., and Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncol 43 (2004) 142-152
251. Nahlé Z. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care 7 (2004) 397-402
252. Alfano C.M., Klesges R.C., Murray D.M., et al. Physical activity in relation to all-site and lung cancer incidence and mortality in current and former smokers. Cancer Epidemiol Biomarkers Prev 13 (2004) 2233-2241
253. Kuriyama S., Tsubono Y., Hozawa A., et al. Obesity and risk of cancer in Japan. Int J Cancer 113 (2005) 148-157
254. Reiche E.M., Nunes S.O., and Morimoto H.K. Stress, depression, the immune system, and cancer. Lancet Oncol 5 (2004) 617-625
255. Bianchini F., and Vainio H. Wine and resveratrol: mechanisms of cancer prevention?. Eur J Cancer Prev 12 (2003) 417-425
256. MacLean C.H., Newberry S.J., Mojica W.A., et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295 (2006) 403-415
257. Visioli F., Grande S., Bogani P., and Galli C. The role of antioxidants in the Mediterranean diets: focus on cancer. Eur J Cancer Prev 13 (2004) 337-343
258. Neuhouser M.L. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 50 (2004) 1-7
259. Klein B.E., Klein R., Lee K.E., and Grady L.M. Statin use and incident nuclear cataract. JAMA 295 (2006) 2752-2758
260. Hennis A., Wu S.Y., Nemesure B., Leske M.C., and Barbados Eye Studies Group. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 122 (2004) 525-530
261. Freeman E.E., Munoz B., Schein O.D., and West S.K. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation Project. Arch Ophthalmol 119 (2001) 1687-1692
262. Wattanapenpaiboon N., and Wahlqvist M.W. Phytonutrient deficiency: the place of palm fruit. Asia Pac J Clin Nutr 12 (2003) 363-368
263. Chasan-Taber L., Willett W.C., Seddon J.M., et al. A prospective study of alcohol consumption and cataract extraction among U.S. women. Ann Epidemiol 10 (2000) 347-353
264. Weintraub J.M., Willett W.C., Rosner B., Colditz G.A., Seddon J.M., and Hankinson S.E. A prospective study of the relationship between body mass index and cataract extraction among US women and men. Int J Obes Relat Metab Disord 26 (2002) 1588-1595